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Abstract  26 
Background 27 
Oxyntomodulin is a natural agonist at both the glucagon receptor (GCGr) and the GLP-1 receptor 28 
(GLP-1r), and peripheral administration reduces food intake and increases energy expenditure in 29 
rodents and humans. Substituting the native glutamine (Gln/Q) at amino acid position 3 of 30 
oxyntomodulin for glutamate (Glu/E) has previously been shown to diminish GCGr activity without 31 
affecting GLP-1r activity. The effects of Glu-3 oxyntomodulin analogues have not been investigated 32 
in rats. 33 
Methods  34 
The effect of two Glu-3 substituted oxyntomodulin-like analogues (OXM14E3 and OXM15E3) on 35 
food intake and bodyweight was investigated in male Wistar rats during 6 days of daily SC 36 
administration. The effects of Glu-3 substitution on analogue binding and activity at the rat glucagon 37 
receptor and rat GLP-1 receptor were investigated in vitro using CHO or CHL cells. 38 
Results 39 
This study reports the novel finding that 25nmol/kg Glu-3 oxyntomodulin-like analogues (OXM14E3 40 
& OXM15E3) significantly increased rat bodyweight by up to 4% compared to the equivalent non 41 
Glu-3 analogues (OXM14 & OXM15), without affecting food intake. The effect of OXM15E3 on 42 
bodyweight was dose dependent. Glu-3 analogues, including Glu-3 oxyntomodulin, decreased 43 
glucagon mediated cAMP accumulation in CHO cells expressing the rat glucagon receptor, 44 
suggesting they may be acting as antagonists.  45 
Conclusion 46 
The results indicate Glu-3 OXM analogues might not be suitable tools to investigate the mechanism 47 
of oxyntomodulin analogue action in a rat model as they significantly increase bodyweight 48 
independently of food intake. Glu-3 OXM analogues are partial agonists at the rat GCGr and may also 49 
act as antagonists, possibly resulting in the observed increase in bodyweight. 50 
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Introduction 54 
The gut-derived hormone oxyntomodulin is a naturally occurring dual agonist of both the glucagon 55 
receptor (GCGr) and GLP-1 receptor (GLP-1r) [1]. Structurally oxyntomodulin is the 29 amino acids 56 
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of glucagon with a C-terminal octapeptide tail [2]. Administration of oxyntomodulin to rodents and 57 
humans reduces food intake and increases energy expenditure, generating significant weight loss and 58 
highlighting oxyntomodulin as a potential pharmacological treatment for obesity [3, 4]. Due to the 59 
short in vivo half-life of native oxyntomodulin [5] it is necessary to produce long lasting analogues 60 
for clinical use.  61 
The dual agonist properties of oxyntomodulin make investigating its mechanism(s) of action 62 
difficult. Using GCGr or GLP-1r antagonists can interfere with the actions of endogenous glucagon 63 
and GLP-1, hormones which play critical roles in glucose homeostasis, therefore giving an inaccurate 64 
picture of oxyntomodulin actions. Alternatively, substituting glutamine at position 3 of 65 
oxyntomodulin (Gln/Q) with glutamate (Glu/E) has previously been reported to diminish GCGr 66 
activity without affecting GLP-1r activity [6, 7] enabling investigation of mechanisms of action 67 
relating to exogenous oxyntomodulin administration. 68 
These Glu-3 oxyntomodulin analogues have been utilised in mice to investigate the 69 
contribution of GCGr and GLP-1r activity to the function of both native oxyntomodulin [7, 8] and a 70 
derivatised analogue [6]. Previous results indicate that oxyntomodulin activity at the GLP-1r is 71 
responsible for the reduction in food intake and activity at the GCGr increases energy expenditure [6, 72 
7]. 73 
Previous work in our lab designed oxyntomodulin-like dual analogues of the GCGr and GLP-74 
1r based on the 29 amino acids of glucagon. A number of conservative amino acid substitutions were 75 
made to increase GLP-1r activity, improve peptide stability and extended circulatory half-life, with a 76 
view to developing a potential treatment for obesity. Several equivalent Glu-3 analogues were also 77 
designed to investigate the contribution of GCGr and GLP-1r activity to the effects of the 78 
oxyntomodulin-like dual analogues. Our pilot experiments suggested that Glu-3 oxyntomodulin-like 79 
analogues increased bodyweight in rats without affecting food intake, therefore further experiments 80 
were undertaken to clarify these findings. The two Glu-3 analogues OXM14E3 and OXM15E3 were 81 
chosen for investigation as they increased bodyweight in a pilot experiment and had similar 82 
conservative amino acid substitutions and pharmacokinetic profiles.  83 
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The results of the current study suggest that Glu-3 substituted oxyntomodulin analogues may 84 
be partial agonists which can act as competitive antagonists in vitro and increase bodyweight 85 
independently of food intake in vivo. Therefore Glu-3 oxyntomodulin analogues are not a suitable 86 
tool to investigate the effects of oxyntomodulin-like dual analogues in a rat model.  87 
 88 
Methods 89 
Compounds 90 
All peptides (human glucagon, GLP-1 and oxyntomodulin; analogues OXM14 and OXM15 and their 91 
respective Glu-3 analogues OXM14E3 and OXM15E3; Glu-3 oxyntomodulin OXME3) were custom 92 
synthesised by Insight Biotechnology Limited (Middlesex, UK) and were >90% pure. The structure of 93 
analogues OXM14E3 and OXM15E3 were based on the 29 amino acids of glucagon and, other than 94 
the Glu-3 substitution, contained 6 single amino acid substitutions between residues 12-29. Both 95 
analogues had additional amino acids at residues 30 and 31 and OXM15E3 was C-terminally 96 
amidated (Figure 1). These analogues were chosen for investigation as they had similar 97 
pharmacokinetic profiles but different affinity and potency at the rat glucagon and GLP-1 receptors.  98 
 99 
Animals 100 
Male Wistar rats (Charles River, Margate, UK) were maintained in individual cages under controlled 101 
temperature (21-23C) and light conditions (12:12 light-dark cycle, lights on at 0700 hours) with ad-102 
libitum access to food (RM1 diet; SDS, Witham, UK) and water unless otherwise stated. All animal 103 
procedures were approved under the British Home Office Animals (Scientific Procedures) Act 1986 104 
(Project Licence 70/7236). 105 
In vivo food intake and bodyweight studies 106 
Prior to study commencement, rats were randomised to treatment groups with equal mean 107 
bodyweights. An injection of peptide (maximum volume 50µl, reconstituted in ZnCl2 to enhance 108 
peptide depot formation [9, 10]) or vehicle (saline) was administered subcutaneously at 1600 hours 109 
daily and food and body weight recorded.    110 
Cell culture 111 
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All cell culture reagents were obtained from Invitrogen (Life Technologies Ltd, Paisley, UK) unless 112 
otherwise stated. CHO-K1 cells over expressing the rGCGr were routinely maintained in DMEM with 113 
25mM glucose and 1mM sodium pyruvate supplemented with 10% FBS, 25mM HEPES, 1% 114 
antibiotic (100U/ml Penicillin and 100µg/ml Streptomycin) and 1 X nonessential amino acids. CHL 115 
cells over expressing the rGLP-1r were maintained in the same DMEM but without additional HEPES 116 
or nonessential amino acids. 117 
 118 
In vitro cAMP accumulation 119 
Levels of cAMP accumulation was measured in chinese hamster ovary (CHO-K1) cells over 120 
expressing the rat GCGr (rGCGr; cDNA from Origene, Cambridge Bioscience, Cambridge, UK) or 121 
chinese hamster lung (CHL) cells over expressing the rat GLP-1r (rGLP-1r; a kind gift from Professor 122 
Bernard Thorens, University of Lausanne, Switzerland).  123 
Cells were seeded in a 48 well plate (Nunc, VWR International Inc, Chicago, USA) in their 124 
respective supplemented DMEM, at a density of 37 500 cells/well (250µl/well) , then incubated for 24 125 
hours. Cells were serum starved in DMEM + 1% antibiotic for 1 hour prior to 30 minutes incubation 126 
at room temperature with peptide concentrations diluted in serum free DMEM with 1mM IBMX 127 
(Sigma-Aldritch, Dorset, UK). Each peptide concentration was applied in duplicate or triplicate per 128 
experiment.  129 
For rat GCGr antagonism studies, cells were incubated for 30 minutes with peptide concentrations 130 
diluted in serum free DMEM with 1mM IBMX and 0.1nM glucagon. Five wells of each concentration 131 
and 12 wells of 0.1nM glucagon alone were applied per experiment.  132 
Post incubation, medium was removed and cells lysed with 120µl /well of 0.1M HCL + 0.5% 133 
Triton-X. cAMP levels were measured using an indirect ELISA according to the manufacturer’s 134 
instructions (ADI-900-066, Enzo Life Sciences, UK), optical density was read at 405nm on a Biotek 135 
ELx808 (Wolf Laboratories, York, UK). Data was plotted and EC50 values calculated. 136 
 137 
In vitro receptor binding- supplementary 138 
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Refer to O’Shea [11] for detailed methods. Briefly, membranes were prepared from CHO-K1 cells 139 
over expressing the rGCGr or CHL cells over expressing the rGLP-1r by osmotic lysis and differential 140 
centrifugation. Membranes (100µg protein) were incubated in siliconised polypropylene tubes with 141 
100pm (500Bq) of either 
125
I-GLP-1 or 
125
I-glucagon in competition with unlabelled peptide. Total 142 
specific binding was calculated as the difference in counts between assays in the presence 143 
(nonspecific) and absence (total) of up to 6000nM of peptides. Data was plotted and IC50 values 144 
calculated. 145 
 146 
Statistical analysis 147 
cAMP EC50’s and binding IC50’s were calculated using non-linear regression with Prism V5 148 
(GraphPad Software Inc. San Diego, CA, USA). Differences in cumulative food intake and body 149 
weight were analysed using one way ANOVA and post hoc tests with Dunnett or Bonferroni 150 
correction (Prism v5, GraphPad Software Inc. San Diego, CA, USA). In all cases P < 0.05 was 151 
considered statistically significant. 152 
 153 
 154 
Results 155 
In vivo 156 
Daily administration of 25nmol/kg OXM14E3 to rats significantly increased bodyweight over 157 
7 days (27.5 ± 2.2g, p < 0.01) compared to vehicle controls (11.4 ± 2.6g) and OXM14 (9.2 ± 3.8g) 158 
(Figure 2.B). Daily 25nmol/kg OXM15E3 administration significantly increased bodyweight over 7 159 
days (19 ± 3.3g, p < 0.01) compared to OXM15 (4.5 ± 2.7g, Figure 2.B). Food intake was not 160 
increased after administration of either OXM14E3 or OXM15E3 (Figure 2.A).  161 
Daily administration of 10nmol/kg and 20nmol/kg of OXM15E3 resulted in a significant 162 
increase in rat bodyweight over 7 days (15.1 ± 1.9g, p < 0.05 and 17.7 ± 1.5g, p < 0.01 respectively) 163 
compared to vehicle controls (7.9 ± 2.0g) (Figure 2.D), without altering food intake (Figure 2.C).  164 
 165 
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In vitro 166 
At the rGCGr the binding affinity of the Glu-3 substituted peptides OXM14E3 and 167 
OXM15E3 was 63 fold and 120 fold lower compared to OXM14 and OXM15 respectively (Figure 168 
3.D). Receptor binding affinity for the Glu-3 analogues at the rGLP-1r was 2.7 - 4.4 fold greater than 169 
their Gln-3 counterparts (Figure 3.D). 170 
Substituting glutamate at position 3 decreased peptide efficacy at the rGCGr. The efficacy of 171 
OXM14E3, OXM15E3 and OXME3 was 200, 25 and 13 fold lower respectively compared to their 172 
Gln-3 equivalents OXM14, OXM15 and OXM. Glu-3 substitution increased rGLP-1r efficacy by 173 
1.2 - 1.6 fold (Figure 3.D).   174 
Concentrations of 0.03-1nM of OXM14E3 (Figure 3.A) and 0.03-0.3nM OXM15E3 (Figure 175 
3.B) decreased the percentage of glucagon mediated cAMP production at the rGCGr by a mean of 176 
18.4% and 27.5% respectively. Concentrations of 3- and 30nM of OXM14E3 and OXM15E3 177 
increased cAMP levels compared to glucagon stimulation alone (OXM14E3 30nM: 155% increase, 178 
OXM15E3 30nM; 214% increase) (Figure 3.A and Figure 3.B respectively). Except 30nM, all 179 
concentrations of OXME3 tested decreased glucagon mediated cAMP accumulation by a mean of 180 
40.3% (Figure 3.C). 30nM OXME3 increased cAMP levels by 9% compared to glucagon stimulation 181 
alone (Figure 3.C). 182 
Conclusions 183 
Structurally, oxyntomodulin is the 29 amino acids of glucagon with a C-terminal octapeptide 184 
tail [2]. The dual agonist activity of oxyntomodulin at the GCGr and GLP-1r makes it difficult to 185 
investigate the mechanisms involved in the weight reducing effects of exogenous oxyntomodulin 186 
administration, as receptor antagonists also block the actions of endogenous glucagon and GLP-1. 187 
Previously it has been reported that exchanging the position 3 glutamine (Gln/Q) of oxyntomodulin or 188 
a related analogue, for glutamate (Glu/E), diminishes mouse GCGr activity without affecting activity 189 
at the mouse GLP-1r [6, 7]. These GLP-1r selective Glu-3 peptides offer an alternative method for 190 
investigating the contribution of GCGr and GLP-1r activity to the metabolic effects of oxyntomodulin 191 
and related analogues. Several previous studies have used Glu-3 analogues to explore the metabolic 192 
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effects of oxyntomodulin administration in mice, reporting that GCGr activity was necessary for [6-193 
8], but the effect of Glu-3 peptide administration in rats has not been investigated. 194 
The current study reports the novel observation that substituting glutamate at position 3 of two 195 
oxyntomodulin-like dual analogues caused a significant increase in bodyweight in a rat model, 196 
without altering food intake. In line with previous findings at the mouse receptor [6, 7], in vitro 197 
activity at the rGCGr was diminished by Glu-3 substitution. Interestingly, glucagon mediated 198 
activation of the rGCGr in vitro was reduced by the lower concentrations of the Glu-3 analogues 199 
tested, including Glu-3 of native oxyntomodulin. This suggests that the Glu-3 OXM analogues may 200 
be partial agonists that can also act as competitive antagonists in vitro, despite reduced rGCGr binding 201 
affinity.  202 
Glucagon administration increases energy expenditure [12, 13] and in rodents this is 203 
postulated to be due to activation of brown adipose tissue (BAT) [14]. Exogenous peripheral 204 
administration of native oxyntomodulin or long acting analogues also increases energy expenditure [3, 205 
4, 6] and several murine studies have suggested a GCGr mediated mechanism is responsible [6, 7]. It 206 
could be speculated that Glu-3 OXM analogues may antagonise the activity of endogenous glucagon, 207 
possibly causing a reduction in energy expenditure and resulting in the observed increase in rat 208 
bodyweight. However endogenous glucagon has not currently been shown to play a tonic role in 209 
energy expenditure or weight regulation. Investigation of the effects of Glu-3 peptides on energy 210 
expenditure in rats is needed. 211 
The increase in bodyweight following Glu-3 administration may be a rat specific 212 
phenomenon, as previous results with Glu-3 oxyntomodulin-like peptides were obtained in mice and 213 
did not show an increase [6, 7]. However Glu-3 peptides used in these previous studies were 214 
derivatised and administered at higher doses than the current study. A recently published study 215 
demonstrated that analogues of glucose-dependent insulinotropic polypeptide (GIP) with a Proline 216 
substitution at amino acid position 3 were full agonists at the human GIP receptor (GIPr) and partial 217 
agonists that could acts as competitive antagonists at the rat and mouse GIPr [15]. It is possible this 218 
may also be the case with Glu-3 oxyntomodulin-like analogues. However, the agonist or antagonist 219 
properties of Glu-3 analogues at the mouse and human GCG receptors have not been fully 220 
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investigated. Additionally, differences in peptide and receptor homology between species may 221 
contribute to the differential effects observed with Pro-3 GIP analogues. Human GIP has several 222 
different residues compared to rat and mouse GIP [15], whereas the amino acid sequences of 223 
glucagon and oxyntomodulin are identical in the 3 species. Therefore the relevance of the findings 224 
with Pro-3 GIP analogues to the current study is unclear. 225 
In conclusion, oxyntomodulin-like analogues with a Glu-3 substitution significantly increase 226 
bodyweight in a rat model, independently of food intake. Glu-3 analogues appear to be be partial 227 
agonists at the rGCGr and can also act as competitive antagonists in vitro. Therefore Glu-3 228 
oxyntomodulin-like analogues are unsuitable tools to investigate the effects of oxyntomodulin 229 
analogue activity in a rat model. 230 
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 280 
Figure 1. Schematic of the amino acid structures of the oxyntomodulin-like dual analogues 281 
investigated in the current study. 282 
 283 
 284 
Figure 2. Food intake (A) and bodyweight change (B) after 7 days of daily SC 25nmol/kg OXM14, 285 
OXM15, OXM14E3, OXM15E3 or vehicle, n=6-7. Food intake (C) and bodyweight change (D) after 7 286 
days of daily SC administration of various doses of OXM15E3 or vehicle, n= 11-12. Data are 287 
presented as mean ± SEM. Statistical analysis was conducted using one-way ANOVA and post hoc 288 
tests with Bonferroni (A, B) or Dunnett (C, D) corrections. *P <0.05, **P <0.01 versus vehicle 289 
controls; 
# #
P <0.01 versus Gln-3 peptide. 290 
 291 
 292 
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 293 
Figure 3. In vitro cAMP levels measured in CHO cells over expressing the rat glucagon receptor 294 
following incubation with various concentrations of OXM14E3 (A), OXM15E3 (B) or OXME3 (C) in the 295 
presence of 0.1nM glucagon. Mean cAMP levels (± SEM) are shown as a percentage of the levels 296 
produced by glucagon stimulation alone, n=3. (D) Mean in vitro efficacy (cAMP EC50) and affinity 297 
(IC50) of oxyntomodulin analogues and native peptides at the rat glucagon receptor (rGCGr) and rat 298 
GLP-1 receptor (rGLP-1r). cAMP EC50 values were calculated using CHO cells over-expressing the 299 
rGCGr or CHL cells over-expressing the rGLP-1r. IC50 values were calculated using membranes 300 
produced from the CHO cells or CHL cells.  n=3. 301 
 302 
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